MMIT Payer Portrait: Health Care Service Corp.

Health Care Service Corporation (HCSC) is the parent company of five large, member owned Blues insurers: Blue Cross and Blue Shield of Illinois, Montana, New Mexico, Oklahoma and Texas. The five subsidiaries enroll more than 16 million lives nationwide across the spectrum of health insurance products, though much of their membership is concentrated in Illinois and Texas. Originally founded in 1936 in Chicago as a prepaid insurance plan for hospital care, HCSC now enrolls more than half of all insured lives in Illinois.

HCSC is a partial owner of its pharmacy benefits manager, Prime Therapeutics, the PBM owned and operated by 18 Blues affiliates. AllianceRx Walgreens Prime, the PBM’s specialty pharmacy partnership with Walgreen Co., handles much of HCSC’s specialty contracting, though BCBS of New Mexico and BCBS of Oklahoma also contract with Cigna Corp.’s Accredo Health Group for specialty drug management.

In March 2021, HCSC unveiled a strategic partnership with Collective Health, a health care startup company whose tech allows employer groups to integrate and manage employee insurance benefits, costs and member health data all on one platform, in addition to providing a personalized, more navigable experience on the consumer end. HCSC then led a $280 million Series F funding round for the startup in May, which the companies said will be used to scale the platform for use by an insurer of HCSC’s size. The transition to Collective Health’s platform will begin with HCSC’s self-funded clients in Illinois and Texas in January 2022.

NOTE: Health Care Service Corp.’s five Blues subsidiaries are represented as separate entities linked by a Parent ID in DHP.

SOURCE: DHP, AIS’s Directory of Health Plans; MMIT Analytics. Learn more about subscribing to AIS Health’s publications here:

Carina Belles

Carina is a reporter at AIS, specializing in public sector data research, trend analysis and infographics. She holds a Bachelor of Science in Journalism from Ohio University, joining AIS shortly after graduating in 2014.

Related Posts
November 18

FDA Grants Interchangeable Status to Humira Biosimilar, but Certain Factors May Hamper Its, Other Adalimumabs’ Uptake

Read More
November 18

Oncologists Show Interest in Prescribing New CML STAMP Inhibitor Scemblix

Read More
November 18

Eli Lilly Pounces on Flailing Aduhelm With Competing Drug

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today